Abstract

Lung cancer has the highest mortality rate as compared to other cancers. The anti-proliferative and antioxidant potential of epigallocatechin gallate (EGCG) and Theaflavin -3,3’-digallate (TF3) can play a major role in treatment if delivered efficiently. To improve the chemical stability and medicinal potential of EGCG and TF3 in the respiratory tract, a spanlastic is developed which is composed of Tween-80, Span-60, and cholesterol which encapsulate EGCG and TF3 inside its vesicular structure and deliver it specifically to the target cancer cells. The cholesterol layer will produce efficient penetration while tween-80 and span-60 will help in easily deformability and lowers the interfacial tension hence, produces a small Z-average diameter which facilitates efficient penetration between layers of cells. The nano-vesicular structure ensures the APIs stability at alkaline pH (7.6) and also increases cellular antioxidant activity and Ferric reducing antioxidant powers values of APIs. Better encapsulation efficiency and safe consideration by MTT assay are major advantages of Spanlastic. The lung cancer cell loses the ability of apoptosis, which can revived with the help of a nano-vesicular system of EGCG and TF3 and in addition, there will be activation of several other properties such as cell arrest, activation of miR-210, suppression of cyclin D1, inhibition of MAPK, ERK, and JAK-STAT at their maximum potential. Furthermore, a special type of spacer and pMDI canister are developed in order to maximize the drug stability and efficiency of its delivery.

Highlights

  • Lung cancer has the highest mortality rate among all cancers

  • epigallocatechin gallate (EGCG) and TF3 nano vesicular systems are prepared through ethanol injection method with Span 60 as non-ionic surfactant and tween-80 as edge activator with an outer covering of lipid

  • Both the EGCG-spanlastic system and TF3 spanlastic system were tested on several bases such as for shape and size TEM imaging will be used, for surface charge and zeta potential poly-dispersity index is measured

Read more

Summary

Introduction

According to the research data of 2018, lung cancer has the highest incidence rates of 20.1 million new cases (12.22/100,000 individuals) and the highest mortality rates of 1.76 million deaths; the death rate is 2 times of breast cancer in women and thrice of prostate cancer [1]. The genetic risk of lung cancer is 2.5 times more [3]. It is a source of 32% of the casualties in men and 20% in women. It has been observed for many years that the incidence rate in blacks is more than in Caucasians [4]. There are several types of lung cancer such as Adenocarcinoma (ADC), Squamous cell carcinoma (SQCC), Small cell carcinoma (SCC), and Large cell carcinoma (LCC) are the major ones but there are some rare types of lungs carcinoma

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call